Millennium Management LLC Has $419,000 Holdings in Cascadian Therapeutics Inc (CASC)

Millennium Management LLC raised its stake in shares of Cascadian Therapeutics Inc (NASDAQ:CASC) by 81.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,300 shares of the biopharmaceutical company’s stock after purchasing an additional 51,000 shares during the period. Millennium Management LLC owned 0.22% of Cascadian Therapeutics worth $419,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC grew its stake in shares of Cascadian Therapeutics by 194.7% in the fourth quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 25,464 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of Cascadian Therapeutics in the fourth quarter worth $181,000. Alps Advisors Inc. acquired a new stake in shares of Cascadian Therapeutics in the fourth quarter worth $207,000. Renaissance Technologies LLC grew its stake in shares of Cascadian Therapeutics by 28.1% in the fourth quarter. Renaissance Technologies LLC now owns 81,688 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 17,900 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Cascadian Therapeutics by 6,622.8% in the third quarter. JPMorgan Chase & Co. now owns 89,413 shares of the biopharmaceutical company’s stock worth $367,000 after acquiring an additional 88,083 shares during the last quarter. Institutional investors own 81.38% of the company’s stock.

CASC opened at $10.02 on Friday. Cascadian Therapeutics Inc has a fifty-two week low of $3.18 and a fifty-two week high of $10.21.

Several brokerages have recently issued reports on CASC. Cantor Fitzgerald set a $10.00 price objective on shares of Cascadian Therapeutics and gave the stock a “hold” rating in a research note on Friday, March 9th. BidaskClub downgraded shares of Cascadian Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 7th. ValuEngine upgraded shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 31st. Finally, Raymond James downgraded shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Cascadian Therapeutics has a consensus rating of “Hold” and a consensus price target of $6.17.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Want to see what other hedge funds are holding CASC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cascadian Therapeutics Inc (NASDAQ:CASC).

Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mackay Shields LLC Acquires Shares of 30,300 LSC Communications
Mackay Shields LLC Acquires Shares of 30,300 LSC Communications
Mackay Shields LLC Invests $553,000 in Range Resources Corp.
Mackay Shields LLC Invests $553,000 in Range Resources Corp.
50,700 Shares in Immersion Co.  Purchased by Mackay Shields LLC
50,700 Shares in Immersion Co. Purchased by Mackay Shields LLC
SG Americas Securities LLC Takes $952,000 Position in Core-Mark Holding Company, Inc.
SG Americas Securities LLC Takes $952,000 Position in Core-Mark Holding Company, Inc.
Schlumberger Limited.  Position Boosted by Zeke Capital Advisors LLC
Schlumberger Limited. Position Boosted by Zeke Capital Advisors LLC
Aecon Group’s  “Outperform Overweight” Rating Reiterated at National Bank Financial
Aecon Group’s “Outperform Overweight” Rating Reiterated at National Bank Financial


Leave a Reply

 
© 2006-2018 Zolmax.